对复发性脑髓母细胞瘤进行"修改-MEMMAT"治疗方案的现实生活经验
Antonella Cacchione1, Giada Del Baldo1,2, Federica D'Antonio1,2
1Department of Pediatric Haematology and Oncology, and Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Therapeutic advances in medical oncology
|September 23, 2025
概括
一种经过修改的计量学抗血管生成疗法对儿童中复发性脑髓母细胞瘤 (MB) 有望. 这种方法在12个月内实现了78.6%的整体存活率,并具有可管理的副作用.
科学领域:
- 儿科瘤学 儿科瘤学
- 癌症治疗方法 癌症治疗方法
- 瘤血管新生 瘤血管新生
背景情况:
- 脑髓母细胞瘤 (MB) 复发是众所周知的对标准治疗具有抗性.
- 向瘤血管生成为MB提供了一个新的治疗策略.
- 综合计学抗血管生成方法是一种新兴的治疗选择.
研究的目的:
- 评估修改的计量学抗血管性策略对儿科复发性MB的疗效和安全性.
- 在这个患者群体中评估生存结果和治疗耐受性.
主要方法:
- 对14名患有复发性MB的儿科患者进行了回顾性观察分析.
- 治疗涉及修改后的Medulloblastoma欧洲多目标计量学抗血管原体试验 (MEMMAT) 策略.
- 对临床,分子,放射和结果数据的分析.
主要成果:
- 患者的中位年龄为11.6岁,所有患者都有转移性复发.
- 平均总生存时间 (OS) 为18.2个月;平均无进展生存时间 (PFS) 为12.8个月.
- 12个月的OS率为78.6%,12个月的PFS率为55.0%.
结论:
- 经过修改的MEMMAT策略表明,在重度预治疗的儿科患者中,复发性MB治疗的潜力.
- 取得了显著的生存率与可管理的毒性.
- 需要在更大的前性研究中进一步验证.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...